FDA to review Merck's treatment for ragweed pollen allergy

05/10/2013 | Fox Business

The FDA has accepted Merck & Co.'s biologics-license application for a dissolvable immunotherapy tablet for ragweed pollen allergy. Merck expects the FDA to release its decision in the first half of next year. The sublingual tablet was developed in collaboration with ALK-Abello.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL